The International Journal of Neuropsychopharmacology
December 3, 2021
Benjamin Hackl, Hannes Todt, Helmut Kubista et al.
11 citations
Abstract Psilocybin, a hallucinogen contained in “magic” mushrooms, holds great promise for the treatment of various psychiatric disorders, and early clinical trials are encouraging. Adverse cardiac events after intake of high doses of psilocybin and a trial reporting QT interval prolongation in the electrocardiogram attributed to the drug’s main metabolite, psilocin, gave rise to safety...
Toxicology and Applied Pharmacology
December 1, 2013
Xaver Koenig, Michael Kovar, Lena Rubi et al.
46 citations
The plant alkaloid ibogaine has promising anti-addictive properties. Albeit not licensed as a therapeutic drug, and despite hints that ibogaine may perturb the heart rhythm, this alkaloid is used to treat drug addicts. We have recently reported that ibogaine inhibits human ERG (hERG) potassium channels at concentrations similar to the drugs affinity for several of its known brain targets....
BMC Pharmacology and Toxicology
September 1, 2012
Xaver Koenig, Michael Kovar, Lena Rubi et al.
The plant alkaloid ibogaine has shown promising anti-addictive properties in animals and humans. Although not licensed as a therapeutic drug, and despite evidence that ibogaine may disturb the rhythm of the heart, this alkaloid is used as an anti-addiction drug in alternative medicine. We have recently reported that therapeutic concentrations of ibogaine inhibit human ERG (hERG) potassium...
BMC Pharmacology
September 5, 2011
Michael Kovar, Xaver Koenig, Ágnes K. Mike et al.
5 citations
Background Ibogaine is an alkaloid derived from the African shrub Tabernanthe iboga. Psychoactive properties of ibogaine have been known for decades, but more recently the drug has received much attention because of its promising “anti-addictive” actions. Thus, ibogaine and its derivatives are being studied as potential treatment for opioid and stimulant abuse, as well as for alcoholism and...